In a recent development, TIRmed has conducted a biodistribution study that has yielded very promising results. The study, focused on dermal applications, marks a significant milestone in the company's ongoing research efforts.

The primary objective of this study was to assess the potential systemic uptake of TIRmed's product TIR-C, specifically into plasma and, if detectable in plasma, its distribution in vital organs such as the heart, liver, kidney, and spleen. To achieve this, TIRmed initiated a 7-day local tolerability study in minipigs, employing a daily application of the product to 10% of the skin surface area. Two different formulations were tested, namely 2% TIR-C and 4% TIR-C, in order to gauge their respective effects.
Utilizing an exceptionally sensitive bioanalytical method with a Lower Limit of Quantification (LLOQ) set at 1ng/ml, a systemic uptake remained essentially undetectable throughout the entire study.

These findings provide evidence that TIRmed's product has a limited distribution within the body, indicating its potential for localized therapeutic effects without significant systemic exposure. This milestone open is a great step in the development of targeted treatments and reaffirms TIRmed's commitment to advancing pharmaceutical research and improving patient outcomes.